By Samuel Indyk
Investing.com – Hikma Pharmaceuticals (LON:) shares have jumped towards the top of the on Wednesday after the company announced it has resumed the launch of its generic version of GlaxoSmithKline’s Advair Diskus.
The news follows US Food and Drug Administration (FDA) approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.
Advair Diskus is a prescription medicine used to treat asthma in patients four years and older.
“We appreciate the FDA’s timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus,” Hikma CEO Siggi Olafsson said in a statement. “We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US.”
At 09:20BST Hikma Pharmaceuticals shares were trading higher by 2.6% at £24.40 per share.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.